Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study
© Shultz et al.; licensee BioMed Central Ltd. 2011
Received: 12 September 2011
Accepted: 16 November 2011
Published: 16 November 2011
Soluble urokinase-type plasminogen activator receptor (suPAR) has been proposed as a biologic marker of fibrinolysis and inflammation. The aim of this study was to investigate the diagnostic and prognostic value of systemic and pulmonary levels of suPAR in burn patients with inhalation trauma who need mechanical ventilation.
suPAR was measured in plasma and nondirected lung-lavage fluid of mechanically ventilated burn patients with inhalation trauma. The samples were obtained on the day of inhalation trauma and on alternate days thereafter until patients were completely weaned from the mechanical ventilator. Mechanically ventilated patients without burns and without pulmonary disease served as controls.
Systemic levels of suPAR in burn patients with inhalation trauma were not different from those in control patients. On admission and follow up, pulmonary levels of suPAR in patients with inhalation trauma were significantly higher compared with controls. Pulmonary levels of suPAR highly correlated with pulmonary levels of interleukin 6, a marker of inflammation, and thrombin-antithrombin complexes, markers of coagulation, but not plasminogen activator activity, a marker of fibrinolysis. Systemic levels of suPAR were predictive of the duration of mechanical ventilation and length of intensive care unit (ICU) stay. Duration of mechanical ventilation and length of ICU stay were significantly longer in burn-injury patients with systemic suPAR levels > 9.5 ng/ml.
Pulmonary levels of suPAR are elevated in burn patients with inhalation trauma, and they correlate with pulmonary inflammation and coagulation. Although pulmonary levels of suPAR may have diagnostic value in burn-injury patients, systemic levels of suPAR have prognostic value.
Soluble urokinase plasminogen activator receptor (suPAR) has recently been recognized as a potential biologic marker of disease. suPAR derives from proteolytic cleavage and release from cell membrane-bound urokinase plasminogen activator receptor (uPAR) and has been detected in different types of body fluids, including blood, urine, cerebrospinal fluid, and pleural, pericardial, and peritoneal fluid [1, 2]. Numerous observational studies show systemic levels of suPAR to be increased with various infectious and inflammatory illnesses [3–9]. In addition, suPAR has been shown to have prognostic value in predicting the outcome of critically ill patients [10–13].
Inhalation trauma is a significant cause of death in patients with burn injury [14, 15] and is associated with increased risks of pneumonia and acute respiratory distress syndrome [16, 17]. Although the diagnosis of inhalation trauma is preferably based on fiberoptic observations, bronchoscopy is an invasive procedure with risk of serious complications . Furthermore, frequently bronchoscopy does not adequately inform on the severity of pulmonary injury [19, 20].
The aim of the present study was to investigate the value of suPAR in the assessment of inhalation trauma in burn patients. We recently investigated markers of inflammation and coagulation in nondirected lung-lavage fluids from burn patients with inhalation trauma . We showed inhalation trauma to be associated with a proinflammatory and procoagulant shift in the bronchoalveolar compartment, similar to that previously shown in patients with acute lung injury . As suPAR has been proposed as a biologic marker of fibrinolysis and inflammation, we hypothesized levels of suPAR to be elevated in lung-lavage fluid of burn patients with inhalation trauma and to correlate with markers of inflammation and coagulopathy. Further, we hypothesized suPAR to have a prognostic value for the duration of mechanical ventilation in burn patients with inhalation trauma. Therefore, we measured levels of suPAR in nondirected lung-lavage fluid and plasma of burn patients with confirmed inhalation trauma and compared them with those in patients without burns or inhalation trauma.
Materials and methods
This observational cohort study was performed in the intensive care units (ICUs) of a regional teaching hospital specialized in care for burn patients (Rode Kruis Ziekenhuis-Burn Center Beverwijk, Beverwijk, The Netherlands) and an academic center (Academic Medical Center, Amsterdam, The Netherlands).
The local medical ethics committees of both hospitals approved the study protocol, and informed consent was obtained from patients or their legal representatives before inclusion.
Patients included in this analysis are identical to those enrolled in an earlier published observational study that originally investigated pulmonary coagulation and fibrinolysis in burn patients with inhalation trauma . The clinical diagnosis of inhalation trauma in burn patients had to be confirmed with bronchoscopy showing soot or infralaryngeal mucosal damage, indicating exposure of the tracheobronchial tree to the physical products of combustion. Patients with neither burn injuries nor inhalation trauma who did not meet the North American European Consensus Conference (NAECC) criteria for ALI/ARDS served as control patients.
Patients were included in the study if they were expected to need mechanical ventilation > 72 hours. Reasons for exclusion were participation in any interventional trials, pregnancy, (suspected) increased intracranial pressure, preexisting severe chronic respiratory disease (defined as a forced expiratory volume in 1 second to forced vital capacity ratio < 0.64, and taking daily medication), (suspected) pneumonia, and the use of corticosteroids or other immunosuppressive agents and intravenously administered heparin.
All patients were mechanically ventilated in a volume-controlled mode with tidal volumes of 6 ml/kg predicted body weight. The levels of positive end-expiratory pressure (PEEP) and inspired oxygen (FiO2) were titrated according to a local protocol. The ventilator was routinely (at least 3 times per day) switched to the pressure-support mode. If the pressure-support mode was tolerated, this mode was used for further mechanical ventilation until tracheal extubation.
Tracheal extubation criteria
Attending physicians decided to remove the translaryngeal tube for mechanical ventilation based on general extubation criteria (that is, responsive and cooperative, adequate oxygenation with FiO2 ≤40%, hemodynamically stable, no uncontrolled arrhythmia, and a rectal temperature > 36.0°C) and no need for repeated surgery during the first week. From the first week, patients were extubated independent of whether a need for surgery existed, even if surgery was planned for the following day, and the first tracheal extubation was counted as the last moment of mechanical ventilation unless a patient needed mechanical ventilation because of continued respiratory insufficiency.
Specimen collection and processing
Blood-sample collection followed by nondirected lung lavage was performed on ICU admission and on alternate days throughout the period of mechanical ventilation. Blood samples were drawn into sterile Vacutainer tubes containing citrate, by using an already in place arterial catheter. Lung lavage was performed by instilling 20 ml of sterile 0.9% saline via a standard 50-cm 14-Fr tracheal suction catheter, as described previously . In short, the distal end of the catheter was introduced via the endotracheal tube and advanced until significant resistance was encountered. Immediately after instillation, over as 10-second period, fluid was aspirated before withdrawal of the catheter. Generally, 4 to 8 ml of fluid was recovered.
Blood and lavage fluid were kept at 4°C until processing, which was performed within 1 hour. Blood and lavage samples were centrifuged for 10 minutes at 4°C at 1,800 g and 800 g, respectively. The supernatants were stored at -80°C until assays were performed.
Demographic data, admission diagnosis, and the extent of burn injury, calculated by using Lund-Bowder charts and expressed as a percentage of the total body surface area (TBSA), were collected. The lung injury score (LIS)  and the oxygenation index (OI)  were calculated.
suPAR was measured by using the suPARnostic kit (ViroGates, Copenhagen, Denmark) according to the recommendations by the manufacturer. Interleukin (IL) 6 was measured by means of commercial enzyme-linked immunosorbent assay (ELISA) kits (Sanquin, Amsterdam, The Netherlands). Thrombin-antithrombin complex (TATc) and plasminogen activator activity (PAA), as reported earlier , were used as markers of coagulopathy.
All data are expressed as medians with their interquartile ranges (IQRs). The nonparametric Mann-Whitney U test was used for comparisons between groups at different time points. Correlation between the extent of burn injury and systemic and local levels of suPAR were assessed with linear regression analysis of the value on admission and the maximal value in each patient during the complete observation period. The nonparametric Spearman test was used for all other correlations. The area under the receiver operating characteristics (ROC) curve was used to calculate the discriminative ability of suPAR. Sensitivity and specificity were calculated according to ROC curves. The rate of freedom from mechanical ventilation or ICU stay was analyzed according to the Kaplan-Meier method, and the results were compared with the log-rank test. A value of P ≤ 0.05 was considered to be statistically significant. PASW version 18.0.0 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism version 5.01 (Graphpad software Inc., San Diego, CA, USA) were used for statistical analyses and drawing figures.
Patients with burn injuries with inhalation trauma (n= 11)
Control patients (n= 15)
Male sex (%)
LIS on admission
TBSA third-degree burns (%)
Burn injuries with inhalation trauma
Asthma cardiale (after MI)
Resuscitation after cardiac arrest
Systemic and pulmonary levels of suPAR
Prediction of inhalation trauma
Correlations between levels of suPAR and inflammation
Correlation between levels of suPAR and coagulopathy
Prognostic value of suPAR
With a cut-off of 9.5 ng/ml, systemic suPAR was a significant discriminator of the duration of mechanical ventilation (AUC, 0.93 (0.73 to 1.0); sensitivity, 100%; specificity, 80%; and ICU-LOS (AUC, 0.93 (0.78 to 1.0); sensitivity, 100%; specificity, 80%) in the burn-injury group).
Repeated surgery during the first week might have delayed the clinical decision to extubate burn-injury patients. This was the case for two patients. After correction for this (that is, the first day of surgery was considered the day of extubation), systemic suPAR remained correlated with the duration of mechanical ventilation (P = 0.02; r = 0.69) and remained a significant predictor of the duration of mechanical ventilation (AUC, 0.96 (0.86 to 1.0); P = 0.01).
To our knowledge, this study is the first to show that suPAR is measurable in lung-lavage fluid. On admission as well as on days 3 and 5, pulmonary levels were consistently higher in burn patients with inhalation trauma as compared with mechanically ventilated patients who were not exposed to fire. Notably, no significant difference was found in systemic levels of suPAR between burn patients and controls. Pulmonary levels of suPAR correlated with inflammation and coagulation, but not with fibrinolysis. Although pulmonary levels of suPAR did not have prognostic value in burn patients, systemic levels of suPAR were predictive of the duration of mechanical ventilation and ICU-LOS.
The observation that pulmonary levels, but not systemic levels of suPAR, were significantly higher in ventilated patients with pulmonary pathology as compared with ventilated controls, suggests the local production of suPAR within the lung. It also indicates that cutaneous burns do not significantly contribute to suPAR levels. This is further exemplified by the finding that TBSA percentage burned and suPAR did not correlate with each other. Notably, it seems that suPAR does not adequately quantify the severity of pulmonary injury, as neither systemic nor pulmonary levels of suPAR correlated with the LIS or the OI. It should be mentioned that we could have failed to detect some small correlations because of the small patient population.
The presence of inhalation injury is not always obvious in burn patients, as pulmonary symptoms may not appear until 24 hours after exposure [26, 27]. An objective confirmation of an inhalation burn, apart from possible therapeutic reasons, is vital for the prognosis. Currently, direct inspection of the airways through bronchoscopy is recommended in patients clinically suspected of inhalation trauma . However, bronchoscopy is an invasive procedure, which may enhance hypoxia in patients with significant airway obstruction. In addition, visualization of tracheobronchial tree beyond the site of obstruction is impossible [18, 28]. Another limiting factor is the availability of experienced personnel. Nonbronchoscopic investigations could be safer, easier, and less physiologically disrupting . Furthermore, nonbronchoscopic sampling can be repeated frequently without a significant burden for the patient. To date, no studies have compared bronchoscopic versus nonbronchoscopic sampling in patients with inhalation trauma. Although bronchoscopy is the gold standard for the diagnosis of inhalation trauma, the present study shows that pulmonary levels of suPAR may discriminate between patients with and without inhalation trauma by using a noninvasive sampling strategy. A bedside test for suPAR will be available soon, giving a readout within 15 minutes. Notably, as recent reviews suggest systemic suPAR not to be a diagnostic marker because of lack of specificity [1, 30], it is plausible that pulmonary suPAR is a general marker of pulmonary inflammation, rather than a specific marker for inhalation injury. This must be addressed in future studies into other lung diseases (for example, pneumonia (hospital acquired, community acquired, or ventilator associated) and ALI/ARDS.
It must be noted, though, that ideally we should have compared suPAR levels in burn patients with and without inhalation injury. This was not possible in our study, because routine diagnostic bronchoscopy is not performed in burn patients without suspected injury, and those patients frequently do not require mechanical ventilation.
Previous investigations showed significantly higher systemic levels of suPAR in critically ill patients as compared with those in healthy controls [2, 9, 10, 31]. Systemic levels of suPAR in these studies were comparable with systemic levels of suPAR in our cohort of critically ill patients. One salient finding was that systemic levels of suPAR were not different between burn patients with inhalation trauma and controls.
Several studies investigated the prognostic value of suPAR in critically ill patients and found systemic levels of suPAR to be predictive of death [9–13, 32]. Although no correlation between systemic levels of suPAR and LOS could be found in a general cohort of ICU patients , systemic suPAR has been shown to correlate with the need for ICU admission and the need for use of vasopressors and mechanical ventilation in critically ill patients . The present study shows suPAR to function as a prognostic marker in burn patients with inhalation trauma as well (that is, high systemic levels of suPAR are predictive for a longer duration of mechanical ventilation and longer ICU-LOS).
Although suPAR has proven to have value as a biologic marker in a variety of pathologic conditions, little is known about the direct biochemical and molecular background of these observations . Although uPA plays a key role in the fibrinolytic pathway, its receptor (uPAR) appears to have little impact on fibrin turnover . Instead, uPAR has been suggested to be involved in the recruitment of monocytes and neutrophils [34, 35]. Inflammatory responses might be mediated by a direct interaction between uPAR and β-integrins [36, 37]. In addition, suPAR has been reported to have direct chemotactic properties [38, 39]. Our findings are consistent with these studies, because we did not observe a correlation between suPAR and fibrinolytic activity. Moreover, the correlation between IL-6 levels and suPAR levels in the lungs indicates that suPAR indeed reflects an enhanced inflammatory state. Given the relation between inflammation and coagulation , one could also expect to find correlations between suPAR and coagulation. A correlation with pulmonary levels of TATc was found in the present study.
We recently investigated pulmonary coagulopathy in patients with inhalation trauma and found a procoagulant and antifibrinolytic shift in the pulmonary compartment . Small trials have shown local anticoagulation therapy to be feasible  and beneficial  in patients with ALI, so this could possibly be an important therapeutic target in patients with inhalation trauma as well. Treatment with nebulized heparin is safe and attenuates lung injury and the progression of acute respiratory distress syndrome in pediatric burn patients with inhalation trauma . At present, we are planning an international multicenter randomized trial of nebulized heparin versus placebo in patients with inhalation trauma. Natural biomarkers of coagulation may be useful in the guidance for this kind of therapy. Presently used markers or measures of local coagulation and fibrinolysis are measurable in lavage fluids by sophisticated laboratory tests, but these are all time consuming and expensive. Given the significant correlation between pulmonary coagulation and pulmonary levels of suPAR, it will be interesting to investigate in future studies whether suPAR can possibly function as guide for local anticoagulant therapy.
A limitation of this study is the sample size. We investigated only 11 burn-injury patients. Besides the small patient population, another limitation is that at baseline, the patients in the control group differed from the patients with burn injuries and inhalation trauma with regard to age. However, it is unlikely that age affected suPAR levels. Although systemic levels of suPAR have been reported to increase slightly with age in healthy subjects , earlier studies on suPAR in critically ill patients did not find a correlation with age [9, 10, 12], possibly because it is masked by their illness. Consistent with this, suPAR also did not correlate with age in our study, in either burn patients or ventilated control patients. Moreover, higher levels of suPAR were found in the younger group and not in the older group.
suPAR is detectable in lung-lavage fluid and is elevated after burns with inhalation injury. Pulmonary suPAR levels correlate with pulmonary inflammatory activity and coagulation, but not with fibrinolysis. Pulmonary suPAR levels may have diagnostic value in burn-injury patients, whereas systemic suPAR levels may have prognostic value.
suPAR is detectable in lung-lavage fluid;
pulmonary levels of suPAR are elevated with inhalation injury in mechanically ventilated burn-injury patients;
measurement of pulmonary levels of suPAR on admission may be useful for the diagnosis of inhalation injury;
pulmonary levels of suPAR correlate with pulmonary inflammatory activity and coagulation, but not with fibrinolysis;
systemic levels of suPAR may be prognostic for duration of mechanical ventilation and length of ICU stay in burn patients with inhalation trauma.
acute lung injury
acute respiratory distress syndrome
area under the curve
enzyme-linked immunosorbent assay
fraction of inspired oxygen
intensive care unit
lung injury score
length of stay
North American European Consensus Conference
- P p :
plasminogen activator activity
positive end-expiratory pressure
- r :
receiver operating characteristic
soluble urokinase plasminogen activator receptor
total body surface area
urokinase plasminogen activator
urokinase plasminogen activator receptor.
The authors thank Dr. JM Binnekade for assistance with the statistical analysis. ViroGates A/S, Denmark, donated the ELISA kits for measuring suPAR free of charge. The company had no influence on study design, results, and the decision to publish results.
- Thuno M, Macho B, Eugen-Olsen J: suPAR: the molecular crystal ball. Dis Markers 2009, 27: 157-172.PubMed CentralView ArticlePubMedGoogle Scholar
- Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF III: Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995, 86: 203-211.PubMedGoogle Scholar
- Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA: Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005, 191: 1331-1341. 10.1086/428854View ArticlePubMedGoogle Scholar
- Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J: Serum levels of soluble urokinase plasminogen activator receptor are associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004, 26: 207-211. 10.1111/j.0141-9838.2004.00695.xView ArticlePubMedGoogle Scholar
- Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H: High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39: 23-31. 10.1097/01.qai.0000157950.02076.a6View ArticlePubMedGoogle Scholar
- Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6: 686-692.PubMedGoogle Scholar
- Garcia-Monco JC, Coleman JL, Benach JL: Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 2002, 129: 216-223. 10.1016/S0165-5728(02)00186-8View ArticlePubMedGoogle Scholar
- Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J: Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36: 14-19. 10.1080/00365540310017366View ArticlePubMedGoogle Scholar
- Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J: The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004, 10: 409-415. 10.1111/j.1469-0691.2004.00850.xView ArticlePubMedGoogle Scholar
- Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15: R63. 10.1186/cc10037PubMed CentralView ArticlePubMedGoogle Scholar
- Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G: Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 2006, 34: 2561-2566. 10.1097/01.CCM.0000239120.32490.ABView ArticlePubMedGoogle Scholar
- Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J: Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, in press.Google Scholar
- Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O: Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008, 27: 375-383. 10.1007/s10096-007-0447-5View ArticlePubMedGoogle Scholar
- Thompson PB, Herndon DN, Traber DL, Abston S: Effect on mortality of inhalation injury. J Trauma 1986, 26: 163-165. 10.1097/00005373-198602000-00012View ArticlePubMedGoogle Scholar
- Suzuki M, Aikawa N, Kobayashi K, Higuchi R: Prognostic implications of inhalation injury in burn patients in Tokyo. Burns 2005, 31: 331-336. 10.1016/j.burns.2004.10.016View ArticlePubMedGoogle Scholar
- Saffle JR, Davis B, Williams P: Recent outcomes in the treatment of burn injury in the United States: a report from the American Burn Association Patient Registry. J Burn Care Rehabil 1995, 16: 219-232. 10.1097/00004630-199505000-00002View ArticlePubMedGoogle Scholar
- Shirani KZ, Pruitt BA Jr, Mason AD Jr: The influence of inhalation injury and pneumonia on burn mortality. Ann Surg 1987, 205: 82-87. 10.1097/00000658-198701000-00015PubMed CentralView ArticlePubMedGoogle Scholar
- Marek K, Piotr W, Stanislaw S, Stefan G, Justyna G, Mariusz N, Andriessen A: Fibreoptic bronchoscopy in routine clinical practice in confirming the diagnosis and treatment of inhalation burns. Burns 2007, 33: 554-560. 10.1016/j.burns.2006.08.030View ArticlePubMedGoogle Scholar
- Ambiavagar M, Chalon J, Zargham I: Tracheobronchial cytologic changes following lower airway thermal injury: a preliminary report. J Trauma 1974, 14: 280-289. 10.1097/00005373-197404000-00002View ArticlePubMedGoogle Scholar
- Woodson LC: Diagnosis and grading of inhalation injury. J Burn Care Res 2009, 30: 143-145. 10.1097/BCR.0b013e3181923b71View ArticlePubMedGoogle Scholar
- Hofstra JJ, Vlaar AP, Knape P, Mackie DP, Determann RM, Choi G, van der Poll T, Levi M, Schultz MJ: Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J Trauma 2011, 70: 1389-1397. 10.1097/TA.0b013e31820f85a7View ArticlePubMedGoogle Scholar
- Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Crit Care Med 2006, 34: 871-877.PubMedGoogle Scholar
- Millo JL, Schultz MJ, Williams C, Weverling GJ, Ringrose T, Mackinlay CI, van der Poll T, Garrard CS: Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 2004, 30: 68-74. 10.1007/s00134-003-2060-0View ArticlePubMedGoogle Scholar
- Murray JF, Matthay MA, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138: 720-723.View ArticlePubMedGoogle Scholar
- Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA: Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med 2010, 11: 12-17. 10.1097/PCC.0b013e3181b0653dPubMed CentralView ArticlePubMedGoogle Scholar
- Herndon DN, Traber DL, Niehaus GD, Linares HA, Traber LD: The pathophysiology of smoke inhalation injury in a sheep model. J Trauma 1984, 24: 1044-1051. 10.1097/00005373-198412000-00007View ArticlePubMedGoogle Scholar
- Demling RH: Smoke inhalation injury. New Horiz 1993, 1: 422-434.PubMedGoogle Scholar
- Gore MA, Joshi AR, Nagarajan G, Iyer SP, Kulkarni T, Khandelwal A: Virtual bronchoscopy for diagnosis of inhalation injury in burnt patients. Burns 2004, 30: 165-168. 10.1016/j.burns.2003.09.024View ArticlePubMedGoogle Scholar
- Fujitani S, Yu VL: Diagnosis of ventilator-associated pneumonia: focus on nonbronchoscopic techniques (nonbronchoscopic bronchoalveolar lavage, including mini-BAL, blinded protected specimen brush, and blinded bronchial sampling) and endotracheal aspirates. J Intensive Care Med 2006, 21: 17-21. 10.1177/0885066605283094View ArticlePubMedGoogle Scholar
- Eugen-Olsen J: suPAR: a future risk marker in bacteremia. J Intern Med 2011, 270: 29-31. 10.1111/j.1365-2796.2011.02372.xView ArticlePubMedGoogle Scholar
- Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J: Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52: 1284-1293. 10.1373/clinchem.2006.067595View ArticlePubMedGoogle Scholar
- Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A: Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011, 30: 1417-1424. 10.1007/s10096-011-1236-8View ArticlePubMedGoogle Scholar
- Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996, 93: 5899-5904. 10.1073/pnas.93.12.5899PubMed CentralView ArticlePubMedGoogle Scholar
- Mondino A, Blasi F: uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004, 25: 450-455. 10.1016/j.it.2004.06.004View ArticlePubMedGoogle Scholar
- Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002, 168: 3507-3511.View ArticlePubMedGoogle Scholar
- Ossowski L, Aguirre-Ghiso JA: Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000, 12: 613-620. 10.1016/S0955-0674(00)00140-XView ArticlePubMedGoogle Scholar
- May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT: Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998, 188: 1029-1037. 10.1084/jem.188.6.1029PubMed CentralView ArticlePubMedGoogle Scholar
- Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996, 15: 1572-1582.PubMed CentralPubMedGoogle Scholar
- Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P: Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005, 105: 2198-2205. 10.1182/blood-2004-06-2424View ArticlePubMedGoogle Scholar
- Choi G, Schultz MJ, Levi M, van der Poll T: The relationship between inflammation and the coagulation system. Swiss Med Wkly 2006, 136: 139-144.PubMedGoogle Scholar
- Dixon B, Santamaria JD, Campbell DJ: A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008, 12: R64. 10.1186/cc6894PubMed CentralView ArticlePubMedGoogle Scholar
- Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14: R180. 10.1186/cc9286PubMed CentralView ArticlePubMedGoogle Scholar
- Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM: Influence of nebulized unfractionated heparin and N -acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009, 30: 249-256. 10.1097/BCR.0b013e318198a268View ArticlePubMedGoogle Scholar
- Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010, 268: 296-308. 10.1111/j.1365-2796.2010.02252.xView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.